NCT00138411View on ClinicalTrials.gov

Monoclonal Antibody for Treatment of Inhalation Anthrax

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 31, 2005

Study Completion Date

March 31, 2006

Conditions
Bacillus Anthracis (Anthrax)
Interventions
DRUG

Ciprofloxacin 500 mg

DRUG

ETI-204 (Anthim)

Trial Locations (1)

43210-1239

Ohio State University, Columbus

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00138411 - Monoclonal Antibody for Treatment of Inhalation Anthrax | Biotech Hunter | Biotech Hunter